Predict your next investment

Venture Capital

See what CB Insights has to offer

Investments

3

Portfolio Exits

1

About Hercules BioVentures Partners

Hercules BioVentures Partners is a California-based venture capital firm.

Hercules BioVentures Partners Headquarter Location

California,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Hercules BioVentures Partners News

BlossomHill Therapeutics Closes $71M Series A Financing

Mar 4, 2021

BlossomHill Therapeutics Closes $71M Series A Financing SAN DIEGO, March 3, 2021-- BlossomHill Therapeutics, Inc., a biopharmaceutical company focusing on oncology and autoimmune disorders, announced today that the company raised $71 million in a Series A financing round. Cormorant Asset Management LLC led this round and is joined by Hercules BioVentures Partners LLC, OrbiMed Advisors, and Vivo Capital as co-leads. In conjunction with the financing, Bihua Chen of Cormorant Asset Management, George J. Lee, Ph.D., of Hercules BioVentures Partners, and Carl L Gordon, Ph.D., CFA, of OrbiMed Advisors joined the company's Board of Directors. "Peter and I founded BlossomHill Therapeutics to continue our pursuit to help bring new hope to cancer patients through deeper science and innovative drug design,” said Dr. J. Jean Cui, Co-Founder, President and CEO. "We are very delighted to have strong support from this group of stellar investors in this Series A round of financing, and to have Bihua, George, and Carl join our Board of Directors." "We are living in a golden age of bringing precision cancer therapy to patients with actionable mutations. Cormorant is privileged to have the opportunity to partner with Dr Cui again to enable her unique drug design capability to bring powerful innovative medicine to patients in need," remarked Bihua Chen, Cormorant Asset Management. “We are excited to partner with Peter & Jean, who have strong insight in identifying key clinical needs and addressing them with targeted small molecule drugs,” commented Carl Gordon, OrbiMed Advisors. Proceeds from the financing will be used to fund the research and development efforts at BlossomHill Therapeutics and advance lead pipeline projects into clinical development. BlossomHill Therapeutics is founded by renowned drug design and development scientist, J. Jean Cui, Ph.D., and biotech veteran, Y. Peter Li, Ph.D., M.B.A. Drs. Cui and Li are also the founders of Turning Point Therapeutics, Inc. About BlossomHill Therapeutics, Inc. BlossomHill Therapeutics, Inc. is a small molecule drug discovery and development company focused on unmet medical needs in oncology and autoimmune disorders. The company is founded by renowned drug design and development scientist, J. Jean Cui, Ph.D. and biotech veteran, Y. Peter Li, Ph.D., M.B.A. Dr. Cui is the lead inventor of multiple oncology medicines and clinical compounds which include Crizotinib, Lorlatinib, Repotrectinib (TPX-0005), TPX-0022, TPX-0046, and TPX-0131.

Hercules BioVentures Partners Investments

3 Investments

Hercules BioVentures Partners has made 3 investments. Their latest investment was in BlossomHill Therapeutics as part of their Series A on March 3, 2021.

CBI Logo

Hercules BioVentures Partners Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

3/1/2021

Series A

BlossomHill Therapeutics

$71M

Yes

2

2/5/2015

Series B

Subscribe to see more

$99M

Subscribe to see more

10

8/28/2014

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

3/1/2021

2/5/2015

8/28/2014

Round

Series A

Series B

Series A

Company

BlossomHill Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$71M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

10

10

Hercules BioVentures Partners Portfolio Exits

1 Portfolio Exit

Hercules BioVentures Partners has 1 portfolio exit. Their latest portfolio exit was Armetheon on March 30, 2017.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

3/30/2017

Merger

1

Date

3/30/2017

Exit

Merger

Companies

Valuation

Acquirer

Sources

1

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.